Skip to main content Skip to main navigation menu Skip to site footer

Liver resection profile in Prof. dr. R.D. Kandou General Hospital: 1-year experience

  • Michael Iskandar ,
  • Michael Tendean ,
  • Toar Deliezer Bram Mambu ,
  • Ferdinand Tjandra ,
  • Jimmy Panelewen ,
  • Celine Martino ,


Background: The role of liver surgery is increasing for primary and secondary liver tumors. One of the most feared complications of liver surgery is Post-Hepatectomy Liver Failure (PHLF). The authors would like to present their experience in a year for liver surgery with morbidity and mortality, including PHLF as evaluation parameters.

Methods: This is a prospective study from July 2019-2020 in a single-center, in which patients with pre-existing liver pathology were assigned to receive liver resection. Types and duration of liver resection, duration of Pringle maneuver, and blood loss were measured. PHLF was evaluated using the ISGLS classification, and morbidity was evaluated using Clavien-Dindo and FABIB classification. The energy device used varies from the harmonic scalpel, ligature, and Thulium-doped fiber laser (TDFL). Data were processed descriptively with IBM SPSS 25 (SPSS Inc., Chicago, USA). Data are presented in descriptive frequency tables as medians and means.

Results: A total of 17 procedures were performed, including minor hepatectomies (58.82 %) and major hepatectomies (41.18%). The mean duration of operation 5.3 hours, the duration of parenchymal transection 91.5 minutes, and the estimated blood loss 1638.2 cc. Vascular occlusion method using Pringle maneuver with mean duration of 31.67 minutes. PHLF incidence found were grade B (5.88 %) and grade C (11.7%), while morbidities by Clavien-Dindo mostly are grade 2 (38.2%) and FABIB classification mostly are Bleeding (45%). The mean postoperative ICU is 3.06days, and the mortality rate is as high as 23.52%.

Conclusion: Liver resection in our center is quite fair judging from the low incidence of PHLF, although the mortality rate is at 23.52%. Due to that, surgical technique and teamwork between units involved need to be improved even further.


  1. Henley SJ, Ward EM, Scott S, Anderson RN, Firth AU, Thomas CC, et al. Annual Report to the Nation on the Status of Cancer , Part I : National Cancer Statistics. 2020;2225–49.
  2. Hepatocellular Carcinoma (HCC): Practice Essentials, Anatomy, Pathophysiology [Internet]. [cited 2020 Jul 24]. Available from:
  3. NIH National Cancer Institute. Cancer Facts & Figures 2020. CA Cancer J Clin [Internet]. 2020;1–76. Available from:
  4. Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver. 2016;10(3):332–9.
  5. Global Cancer Observatory [Internet]. [cited 2020 Jul 25]. Available from:
  6. Globocan Observatory W. Cancer Today - World. Int Agency Res Cancer [Internet]. 2019;876:2018–9. Available from:
  7. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol [Internet]. 2013;58(3):593–608. Available from:
  8. Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci [Internet]. 2019 Jan 1 [cited 2020 Jul 25];24(1):86. Available from:
  9. Griscom JT, Wolf PS. Cancer, Liver Metastasis [Internet]. StatPearls. StatPearls Publishing; 2020 [cited 2020 Jul 26]. Available from:
  10. Sherman M. Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30(1):3–16.
  11. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet [Internet]. 2012;379(9822):1245–55. Available from:
  12. Chittmittrapap S, Chieochansin T, Chaiteerakij R, Treeprasertsuk S, Klaikaew N, Tangkijvanich P, et al. Prevalence of aflatoxin induced p53 mutation at codon 249 (r249s) in hepatocellular carcinoma patients with and without Hepatitis B surface antigen (HBsAg). Asian Pacific J Cancer Prev. 2013;14(12):7675–9.
  13. Goh GBB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol [Internet]. 2015;29(6):919–28. Available from:
  14. Lim KC, Wang VW, Siddiqui FJ, Shi L, Chan ESY, Oh HC, et al. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology. 2015;61(1):227–37.
  15. Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol. 2018;24(32):3626–36.
  16. Tanaka K. Resection versus transplantation for hepatocellular carcinoma exceeding Milan criteria within increasing donor shortage. HepatoBiliary Surg Nutr. 2017;6(4):280–3.
  17. Zhong JH, Ke Y, Gong WF, Xiang B De, Ma L, Ye XP, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–40.
  18. Zou H, Tao Y, Wang ZM. Integration of Cild-Pugh score with future liver remnant yields improved prediction of liver dysfunction risk for HBV-related hepatocellular carcinoma following hepatic resection. Oncol Lett. 2017;1.

How to Cite

Iskandar, M., Tendean, M., Mambu, T. D. B., Tjandra, F., Panelewen, J., & Martino, C. (2021). Liver resection profile in Prof. dr. R.D. Kandou General Hospital: 1-year experience. Bali Medical Journal, 10(1), 47–52.




Search Panel

Michael Iskandar
Google Scholar
BMJ Journal

Michael Tendean
Google Scholar
BMJ Journal

Toar Deliezer Bram Mambu
Google Scholar
BMJ Journal

Ferdinand Tjandra
Google Scholar
BMJ Journal

Jimmy Panelewen
Google Scholar
BMJ Journal

Celine Martino
Google Scholar
BMJ Journal